Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use.
The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.
Related articles:
Related suggestion:
Government increases support for Ukraine, extends NZDF deploymentCJ McCollum scores 28 points as Pelicans hold off Warriors 114Boston Red Sox shortstop Trevor Story has seasonWrexham eyes another promotion, this time to 3rd tier of English soccerWashington man pleads guilty to groping woman on San Diego to Seattle flightDemocratic donors paid more than $1M for Biden's legal bills for special counsel probeGovernment increases support for Ukraine, extends NZDF deploymentBiden could miss the deadline for the November ballot in AlabamaCalifornia court affirms Kevin McCarthy protege's dual candidacies on state ballotInternational migrants were attracted to large urban counties last year, Census Bureau data shows
2.7694s , 6497.578125 kb
Copyright © 2024 Powered by Medicare can pay for obesity drugs like Wegovy in certain heart patients ,World Wonders news portal